CompletedPHASE1, PHASE2NCT04051307

Dual Vaccine Trial in Myeloproliferative Neoplasms

Studying Essential thrombocythemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Inge Marie Svane
Principal Investigator
Jacob H Grauslund, MD
CENTER FOR CANCER IMMUNE THERAPY, CCIT-DK
Intervention
PD-L1 peptide: PD-L1 Long(19-27) Peptide sequence: FMTYWHLLNAFTVTVPKDL(drug)
Enrollment
9 enrolled
Eligibility
18 years · All sexes
Timeline
2019 – 2022

Study locations (2)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04051307 on ClinicalTrials.gov

Other trials for Essential thrombocythemia

Additional recruiting or active studies for the same condition.

See all trials for Essential thrombocythemia →

← Back to all trials